Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Susana Gomez Garcia"'
Autor:
Eitan Amir, Alberto Ocaña, Arnoud J. Templeton, Bostjan Seruga, Susana Gomez Garcia, Tristan A. Barnes, Beatriz Navarro
Publikováno v:
Cancer treatment reviews. 56
e18336 Background: New anti-cancer drugs utilize diverse mechanisms of action. Here we evaluate their differential efficacy, safety, tolerability and price. Methods: Drugs approved for the treatment of solid tumors between 2000 and 2015 were identifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35cad6cbfd5093cf66b04fd275e1632
https://pubmed.ncbi.nlm.nih.gov/28437678
https://pubmed.ncbi.nlm.nih.gov/28437678
Publikováno v:
European journal of cancer (Oxford, England : 1990). 63
The principal objective for any medical therapy is to improve either the duration of life and/or its quality. Metastases in bone can lead to clinically defined events termed skeletal-related events (SREs) which are a quantifiable measure of skeletal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d62fd322a78e99db53ac4b4cf244866b
https://pubmed.ncbi.nlm.nih.gov/27299662
https://pubmed.ncbi.nlm.nih.gov/27299662
Autor:
Enrrique Castro, F.J. Afonso, Marinha Costa Rivas, Mª Carmen Areses Manrique, Susana Gomez Garcia, Noemi De Dios Alvarez, Jorge Garcia, Margarita Amenedo, Cristina Azpitarte, Joaquin Casal Rubio, Jl Firvida, B. Campos, Manuel Caeiro, Ines Formoso, Natalia Fernández Núñez, Patricia Calvo
Publikováno v:
Journal of Clinical Oncology. 35:e20067-e20067
e20067 Background: Platinum-based CChRT is recommended as the evidence-based approach for the management of patients (p) with locally advanced stage III NSCLC and a good performance status, although a clearly superior regimen has not been identified.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::872281607580163029c3fd1bcdd63ca2
https://doi.org/10.1200/jco.2017.35.15_suppl.e20067
https://doi.org/10.1200/jco.2017.35.15_suppl.e20067
Autor:
Monica Alvarez, Begoà ±a Campos Balea, Ana Herrero, Marinha Costa Rivas, Susana Gomez Garcia, Carolina Pena, Natalia Fernandez Nunez, Lorena Cadavid Vieitez, Sergio Vazquez-Estevez, Margarita Amenedo, Marta Covela Rúa, José Luis Fírvida Pérez
Publikováno v:
Journal of Clinical Oncology. 34:e20533-e20533
e20533Background: Median overall survival (mOS) of SqLC is 9-10 months, despite treatment with platinum combinations. The ERCC1 expression is related to platinum resistance, so it could help to sel...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa5f2ce2bc6731459f2769913e9aada7
https://doi.org/10.1200/jco.2016.34.15_suppl.e20533
https://doi.org/10.1200/jco.2016.34.15_suppl.e20533